速递 | 12周减重8.9%！德睿智药GLP-1每日一次口服药物取得积极临床进展

Core Viewpoint - The article discusses the promising results of the oral small molecule GLP-1 receptor agonist MDR-001 developed by Derui Zhiya, which shows significant weight loss in overweight or obese individuals after a 12-week treatment period [2][3]. Group 1: Study Results - The study included 24 adult participants, randomly assigned in a 2:1 ratio to receive either MDR-001 or a placebo for 12 weeks [3]. - The MDR-001 group experienced an average weight loss of 8.9%, compared to 0.6% in the placebo group, resulting in a net weight loss of 8.3% after adjusting for placebo effects [2][3]. - 93.8% of participants in the MDR-001 group achieved at least a 5% weight loss, and 37.5% achieved at least a 10% weight loss, with beneficial changes observed in various metabolic and cardiovascular indicators [3]. Group 2: Safety and Tolerability - The overall safety and tolerability of MDR-001 were reported to be good, with no serious adverse events noted during the trial [3]. - The most common side effects were gastrointestinal reactions, which were mostly mild to moderate and manageable [3]. Group 3: Comparison with Previous Studies - The article highlights that in a previous Phase IIb study using a "twice daily" (BID) dosing regimen, a weight loss of 10.3% was reported over 24 weeks, indicating that the current "once daily" (QD) regimen provides new evidence for dosing frequency optimization and long-term validation [3].